Hospital
Asante Ashland Community Hospital, LLC
Asante Ashland Community Hospital, LLC was paid $8.99M by Medicaid between May 2018 and Nov 2024, across 42 billing codes. Its largest line is 99283, emergency room visit (moderate) — 50% of everything it billed.
33Billing provider infoASANTE ASHLAND COMMUNITY HOSPITAL, LLC
ASHLAND, OR 97520
ASHLAND, OR 97520
33aNPI1730628827assigned 02/22/2017
33bProvider typeMedicare Defined Swing Bed Hospital Unit
28Total paid$8.99M
24GClaims54,539
24DCodes billed42
24AFirst – last monthMay 2018 – Nov 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 4,224 | $537K | |
| 2019 | 7,410 | $957K | |
| 2020 | 5,809 | $816K | |
| 2021 | 7,525 | $1.06M | |
| 2022 | 10,101 | $1.55M | |
| 2023 | 9,639 | $1.81M | |
| 2024incomplete | 9,831 | $2.27M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 50% | 22,108 | 14,251 | $4.51M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 32% | 10,118 | 7,274 | $2.90M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 4.5% | 1,359 | 542 | $405K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.6% | 1,571 | 1,158 | $236K |
| 80053 | Comprehensive metabolic panel | 2.5% | 4,542 | 4,201 | $225K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.2% | 4,902 | 4,523 | $200K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.5% | 1,789 | 810 | $131K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.1% | 205 | 181 | $100K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.1% | 368 | 338 | $98K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 150 | 137 | $21K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 157 | 149 | $21K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 198 | 175 | $19K |
30 more codes
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 184 | $19K |
| 71045 | Radiologic examination, chest; single view | <1% | 103 | $13K |
| 81003 | <1% | 374 | $13K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,836 | $11K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 68 | $11K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 246 | $8K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,597 | $7K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 20 | $6K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 15 | $4K |
| 97597 | <1% | 35 | $4K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 43 | $4K |
| 80061 | Lipid panel | <1% | 237 | $3K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 74 | $3K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 159 | $3K |
| A6212 | Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing | <1% | 561 | $2K |
| 84484 | <1% | 35 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 87 | $2K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 12 | $1K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 67 | $1K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 42 | $1K |
| 83690 | <1% | 14 | $1K | |
| 83735 | <1% | 13 | $969.12 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 63 | $801.08 |
| 81001 | <1% | 15 | $595.33 | |
| A6213 | Foam dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., with any size adhesive border, each dressing | <1% | 57 | $422.74 |
| J2704 | Injection, propofol, 10 mg | <1% | 12 | $361.88 |
| 84439 | <1% | 26 | $339.77 | |
| A6207 | Contact layer, sterile, more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | <1% | 23 | $215.23 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 14 | $55.67 |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | 0% | 40 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialROWENHORST, HEATHER (CHIEF FINANCE OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Asante | Medford, OR | $29.67M |
| Asante Three Rivers Medical Center, LLC | Grants Pass, OR | $27.57M |
| Asante | Medford, OR | $5.34M |
| Asante Three Rivers Medical Center LLC | Grants Pass, OR | $5.17M |
| Asante Community Services LLC | Medford, OR | $938K |
| Asante Three Rivers Medical Center, LLC | Grants Pass, OR | $64K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.